TB-500 Legal Status, FDA 503A Category, and Compounding Access

The current FDA fact

TB-500 legal status begins with one citable fact. FDA lists this substance as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500," and placed it in 503A "Category 2" — bulk drug substances that may present significant safety risks — effective with FDA's September 29, 2023 update to the list of nominated substances, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information ^[16].

Two consequences follow directly. As a Category 2 substance, TB-500 is not within FDA's enforcement-discretion policy for 503A compounding: FDA has stated it would consider taking action against a compounder for compounding with a Category 2 substance ^[17]. And separately, TB-500 is not an FDA-approved drug — no New Drug Application or Biologics License Application has been approved for it ^[16]. FDA approval of a finished drug and eligibility of a bulk substance for compounding are two different questions, and TB-500 clears neither.

FDA's own list entry is also the source for the molecule's identity here: it ties "TB-500" to the LKKTETQ fragment of thymosin beta-4 in a single entry ^[16]. That is the same fragment-versus-protein distinction this site tracks throughout.

What is under active review

Access is under active FDA review and may expand in 2026 — and the anchor for that statement is concrete. TB-500, listed as "TB-500 (free base)" and "TB-500 acetate," is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" ^[18]. The same agenda also lists BPC-157, KPV, and MOTs-C.

That is the honest shape of the news: a scheduled evaluation and discussion, nothing more. Being discussed by PCAC is a step in FDA's evaluation, not a final listing decision — a PCAC discussion is advisory, and inclusion on a final bulks list is decided by FDA rulemaking ^[17][18]. No outcome of the July 2026 meeting should be assumed, stated, or dated, and this page does not predict one.

It is worth being equally clear about what this page will not claim. Some commercial and clinic sources have reported an early-2026 expectation that roughly 14 of the Category 2 peptides would move back toward Category 1, and some have asserted specific 2026 dates on which TB-500 or related peptides were "removed" from Category 2. Those reports could not be confirmed from an authoritative FDA source, and the most candid of them concede the formal reclassification is still pending ^[18]. The current status stated here remains Category 2, the last FDA action confirmable from FDA.gov. No reclassification is presented as done, dated, or certain.

How legally compounded peptide access works

U.S. drug compounding runs on two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight and FDA inspection ^[17].

The lawful pathway is a sequence, not a shortcut. A patient is first evaluated by an appropriately licensed prescriber — in person or through a compliant telehealth encounter — who determines whether a compounded preparation is clinically appropriate. If it is appropriate and lawful, the prescriber issues a valid, patient-specific prescription. That prescription is then dispensed by a state-licensed 503A pharmacy, or, for office and batch use, sourced from an FDA-registered 503B facility ^[17].

Telehealth, where it appears, is only the front-end channel for that prescriber evaluation — a route to a licensed consultation and prescription. It does not change which substances may be compounded and does not remove the need for a legitimate clinical evaluation and a valid prescription ^[17].

The ingredient-eligibility caveat is what makes TB-500 a special case. A compounder may use a bulk drug substance only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on the relevant FDA bulks list ^[17]. A substance FDA has flagged for significant safety risks — a Category 2 substance such as TB-500 — is not eligible for routine 503A compounding while that status stands ^[16][17]. So the access question for TB-500 is not really about finding a prescriber or a pharmacy; it is about whether the ingredient itself is currently eligible, and under the present FDA status it is not.

Anti-doping and veterinary standing

Beyond the compounding framework, TB-500 carries a separate regulatory mark: it is prohibited in sport. TB-500 and thymosin beta-4 fall under the World Anti-Doping Agency's prohibited peptide, growth-factor, and tissue-repair categories, and are detected by liquid-chromatography mass-spectrometry anti-doping assays in equine and human matrices. The compound's analytical history is bound up with horse racing, where it surfaced as a designer peptide and prompted the first detection methods for the parent peptide and its metabolites in equine plasma and urine.

This information is general background on the regulatory landscape. It is not medical or legal advice, and nothing on this page is an offer to sell or supply any substance.